OpGen

OpGen Equity

The The Equity of OpGen (OPGN) as of Oct 22, 2026 is 31.86 M USD. In the previous year, The Equity was 7.38 M USD — a change of 331.63% (higher).

Equity

31.86 MUSD

YoY

331.63%

Last updated:

In 2025, OpGen's equity was 31.86 M USD, a 331.63% increase from the 7.38 M USD equity in the previous year.

The OpGen Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
3.31 M USD
Jan 1, 2019
4.29 M USD
Jan 1, 2020
21.19 M USD
Jan 1, 2021
41.22 M USD
Jan 1, 2022
7.58 M USD
Jan 1, 2023
-11.56 M USD
Jan 1, 2024
7.38 M USD
Jan 1, 2025
31.86 M USD
The OpGen Equity history
YEAREquityYoY
31.86 MUSD+331.63%
7.38 MUSD-163.84%
-11.56 MUSD-252.61%
7.58 MUSD-81.62%
41.22 MUSD+94.50%
21.19 MUSD+393.58%
4.29 MUSD+29.76%
3.31 MUSD+136.17%
1.40 MUSD-55.77%
3.17 MUSD-57.72%
7.49 MUSD-192.88%
-8.07 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen is one of the most popular companies on Eulerpool.

Equity Details

Analyzing OpGen's Equity

OpGen's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding OpGen's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating OpGen's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

OpGen's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in OpGen’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about OpGen stock

The Equity of OpGen is 31.86 M USD in 2025.

The Equity of OpGen changed from 7.38 M USD to 31.86 M USD, representing a 331.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity OpGen since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's OpGen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — OpGen

All Key Metrics — OpGen